Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NovaDigm Therapeutics

Request full access

Develops vaccines that protect patients from contracting fungal and bacterial infections

Grand Forks, United StatesFounded 2005Biotech & Life Sciences

About NovaDigm Therapeutics

NovaDigm Therapeutics is a biotechnology company focused on developing innovative immunotherapeutics and preventative vaccines to combat fungal and bacterial diseases. These diseases can be recurrent, drug-resistant, and potentially life-threatening. The company's lead development candidate, NDV-3A, is the first vaccine to show preclinical efficacy in reducing the severity of diseases caused by both fungal and bacterial pathogens. NDV-3A is currently in Phase 2 clinical development for treating recurrent vulvovaginal candidiasis (RVVC), with plans for additional indications in the future.

NovaDigm serves patients who suffer from recurrent and drug-resistant infections, primarily targeting the healthcare market. The company's business model revolves around the research, development, and eventual commercialization of its vaccine candidates. Revenue is expected to be generated through the successful approval and sale of these vaccines, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
2
Open positions
None listed
Dealroom signal
25.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Vaccines, Bacteria, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Jun 2017 $6M — US Department of War —
SERIES BOther financing Nov 2014 $7M $28M RMI Partners —
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

NovaDigm Therapeutics website traffic

Latest recorded traffic for NovaDigm Therapeutics is 2.3K monthly website visits, up 21.1% over the last three months. NovaDigm Therapeutics's team grew 0% over the past year.

Latest monthly visits2.3K 3-month web change+21.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

NovaDigm Therapeutics in the Grand Forks ecosystem

Live from Dealroom

The NovaDigm Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • US Department of War

Series A2 investors entered at this stage

  • Domain Associates
  • RMI Partners

Other known investors1 additional known investor

  • UMass Lowell
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NovaDigm Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NovaDigm Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.